VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients

Among the possible genetic contributors to cancer-related venous thromboembolism (VTE), vascular endothelial growth factor (VEGFA) could play an important role, as an imbalance of the VEGFA system (either disease-related or drug-induced) may result in a disturbance of vascular homeostasis. Thus, this study was designed to investigate the predictive role of eight different VEGFA gene promoter single nucleotide polymorphisms (SNPs) for a first VTE episode in cancer out-patients undergoing chemotherapy. To this purpose, VEGFA gene promoter polymorphisms were analysed in 297 cancer patients using polymerase chain reaction amplification and direct DNA sequencing analysis. One hundred forty unrelated healthy subjects from the same geographical area were also analysed in order to evaluate and compare genotype/haplotype frequencies in our ethnicity. VTE occurred in 26 (9%) of cancer patients with a median time-to-event of 3.4 months. Association analyses showed that -1154G/A polymorphism was significantly associated with the risk of chemotherapy-triggered VTE, with the A allele exerting a protective role both in the overall population (hazard ratio [HR]: 0.21; 95% confidence interval [CI]: 0.07-0.58) or in bevacizumab-treated metastatic patients (HR: 0.09, 95%CI: 0.01-0.86) in whom VEGFA -1154AA genotype also conferred a reduced risk of early progression (HR: 0.58, 95%CI: 0.34-0.98). These results suggest that VEGFA may represent a candidate gene contributing to VTE development in chemotherapy treated cancer patients and that -1154G/A SNP might provide useful clinical information on the efficacy and toxicity of bevacizumab in metastatic patients. Validation studies are needed for translation into clinical practice.

[1]  B. Brenner,et al.  Thrombophilia and Cancer , 2007, Pathophysiology of Haemostasis and Thrombosis.

[2]  J. Vadgama,et al.  Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. , 2002, International journal of oncology.

[3]  A. Siegbahn,et al.  Tissue factor non‐coagulant signaling – molecular mechanisms and biological consequences with a focus on cell migration and apoptosis , 2013, Journal of thrombosis and haemostasis : JTH.

[4]  S. Basili,et al.  In vivo platelet activation is associated with increased plasma levels of vascular endothelial growth factor , 2003, Journal of thrombosis and haemostasis : JTH.

[5]  F. Guadagni,et al.  Prognostic Value of Vascular Endothelial Growth Factor Tumor Tissue Content of Colorectal Cancer , 2005, Oncology.

[6]  F. Rosendaal,et al.  Malignancies, prothrombotic mutations, and the risk of venous thrombosis. , 2005, JAMA.

[7]  Hong Ma,et al.  Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis , 2013, World Journal of Surgical Oncology.

[8]  E. Ingham,et al.  Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.

[9]  F. Guadagni,et al.  Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies. , 2012, Current vascular pharmacology.

[10]  A. Dudek,et al.  Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer: Correlation with Treatment Response and Survival , 2005, Cancer investigation.

[11]  B. Karlan,et al.  Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. , 2013, Gynecologic oncology.

[12]  K. Matsuo,et al.  Predictive model of venous thromboembolism in endometrial cancer. , 2013, Gynecologic oncology.

[13]  S. Iacobelli,et al.  Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy , 2010, Thrombosis and Haemostasis.

[14]  R. Berardi,et al.  Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  E. Kobyliansky,et al.  Heritability of circulating growth factors involved in the angiogenesis in healthy human population. , 2004, Cytokine.

[16]  C. Marosi,et al.  Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS) , 2015, Journal of thrombosis and haemostasis : JTH.

[17]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[18]  D. Cunningham,et al.  Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection , 2012, British Journal of Cancer.

[19]  S. Visvikis-Siest,et al.  Heritability for Plasma VEGF Concentration in the Stanislas Family Study , 2007, Annals of human genetics.

[20]  H. Verheul,et al.  Platelet: transporter of vascular endothelial growth factor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  F. Guadagni,et al.  VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. , 2010, Clinical biochemistry.

[22]  D. Schoenfeld,et al.  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. , 1982, Biometrics.

[23]  Sebastian M. Armasu,et al.  A Genome‐Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium , 2013, Genetic epidemiology.

[24]  F. Fabris,et al.  Validation of Blood Collection Procedures for the Determination of Circulating Vascular Endothelial Growth Factor (VEGF) in Different Blood Compartments , 2001, The International journal of biological markers.

[25]  H. Versteeg,et al.  Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor? , 2014, Thrombosis research.

[26]  Genetic markers of bevacizumab-induced hypertension , 2014, Angiogenesis.

[27]  M. Espié,et al.  Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. , 2011, British journal of clinical pharmacology.

[28]  F. Guadagni,et al.  Impact of chemotherapy on activated protein C‐dependent thrombin generation—Association with VTE occurrence , 2013, International journal of cancer.

[29]  Maria Laura De Marchis,et al.  Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab , 2011, International Journal of Colorectal Disease.

[30]  Jerry Younger,et al.  VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy , 2008, Clinical Cancer Research.

[31]  Ikuo Inoue,et al.  A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. , 2002, Diabetes.

[32]  Joan Valls,et al.  SNPStats: a web tool for the analysis of association studies , 2006, Bioinform..

[33]  F. Guadagni,et al.  Thromboembolic events in patients treated with anti-angiogenic drugs. , 2009, Current vascular pharmacology.

[34]  E. Perez,et al.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  F. Guadagni,et al.  TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  F. Guadagni,et al.  Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity. , 2015, Pharmacogenomics.

[37]  H. Akaike.  A Bayesian analysis of the minimum AIC procedure , 1978 .

[38]  S. Rafii,et al.  Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Y. Ando,et al.  Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer , 2013, Cancer Chemotherapy and Pharmacology.

[40]  J. Kujovich.  Factor V Leiden thrombophilia , 2011, Genetics in Medicine.

[41]  R. Vasan,et al.  Identification of cis- and trans-Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels , 2011, Circulation research.

[42]  Chao Guo,et al.  Effect of tissue factor on invasion inhibition and apoptosis inducing effect of oxaliplatin in human gastric cancer cell. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[43]  A. Ozet,et al.  A rare occurrence of diffuse lymphoblastic lymphoma in pregnancy , 2007, American journal of hematology.

[44]  M. Bottomley,et al.  Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. , 2000, Cytokine.

[45]  H. Chew,et al.  The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer , 2010, Cancer.

[46]  A. Leutenegger,et al.  Genetics of VEGF Serum Variation in Human Isolated Populations of Cilento: Importance of VEGF Polymorphisms , 2011, PloS one.

[47]  A. Khorana,et al.  Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United States , 2013, Cancer.

[48]  F. Guadagni,et al.  Clinical models and biochemical predictors of VTE in lung cancer , 2014, Cancer and Metastasis Reviews.

[49]  G. Sledge,et al.  Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. , 2013, The oncologist.

[50]  P. Mannucci,et al.  Inherited risk factors for venous thromboembolism , 2014, Nature Reviews Cardiology.

[51]  S. Barni,et al.  Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  I. Majsterek,et al.  An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.